FDA Permits Stem Cell Clinical Trial for Stargardt to Begin

by Retina Today • 2010/12/02 • 0 Comments

Advanced Cell Technology, Inc. (Santa Monica, CA), has received clearance from the FDA to conduct a phase 2/3 clinical trial using retinal pigment epithelium (RPE) cells derived from human embryonic stem cells to treat patients with Stargardt macular dystrophy (SMD), according to a company news release. The decision re...

← Omega-3s In Fish, Seafood May Protect Seniors’ Eyes; A New Test May Catch Glaucoma Early

A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent →

Post navigation